alexa Two Cases Lung Cancer Successfully Treated with 4-Hydroxybenzaldehyde after Surgical Operations | OMICS International
Journal of Lung Cancer Diagnosis & Treatment

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Two Cases Lung Cancer Successfully Treated with 4-Hydroxybenzaldehyde after Surgical Operations

Kimihiko Okazaki*

Department of Dermatology, Okazaki Medical Clinic, Ukyoku, Kyoto, Japan

*Corresponding Author:
Kimihiko Okazaki
Department of Dermatology, Okazaki Medical Clinic
Ukyoku, Kyoto, Japan
Tel: +8175753753
E-mail: [email protected]

Received date: July 21, 2017; Accepted date: July 29, 2017; Published date: August 05, 2017

Citation: Okazaki K (2017) Two Cases Lung Cancer Successfully Treated with 4-Hydroxybenzaldehyde after Surgical Operations. J Lung Cancer Diagn Treat 2:116.

Copyright: © 2017 Okazaki K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Lung Cancer Diagnosis & Treatment

Case Report

In 1985, Kochi [1,2] reported a novel anti-tumor agent after acquiring a Japanese Patent in 1969. According to his patent, 4- Hydroxybenzaldehyde is an anti-tumor agent without any side-effects. My impression is that this stuff is capable of preventing carcinogenesis when used quantitatively sufficiently. In order to treat developed cancers, you ought to start giving your cancer patient a small dose of the stuff because, otherwise, the patient may suffer from a serious hemorrhage of the tumor caused by excessive necroses. Therefore, lymphomas and leukemias can be treated more easily because these tumors have no blood vessels. Consequently, those who have these diseases can receive considerably large dose of the stuff.

Case 1: A 71-year-old woman (MS) visited my clinic on November 12, 2014. She told me that she had undergone a surgical operation extirpating the lower part of the upper lobe and upper part of the lower lobe of her left lung due to presence of multiple tumors of small cell lung cancer, size of each tumor being less than 1cm, on March 19, 2014. To prevent recurrence of the tumor, she took 4 cures of Cisplatin. I prescribed 5 mg daily of 4-Hydroxybenzaldehyde; 1 mL of aqueous solution of 500 mg% per os for 4 weeks, raising the daily dose by 40% every 4 weeks until the daily dose reached 50 mg. Then, I raised the dose to 63 mg/day for 32 days. I kept raising the doses, namely, daily 83 mg for 36 days, daily 111 mg for 63 days, daily 167 mg for 54 days, daily 222 mg for 90 days, daily 333 mg for 18 days, daily 500mg for 56 days, daily 667 mg for 24 days, daily 1 g for 52 days, daily 1.5 g for 112 days, daily 2 g for 115 days, and daily 3 g since April 26, 2017. She is currently taking 3 g every day. Her blood-tests showed an instability in neuron-specific enolase activity; a tumor marker of lung cancer, as follows: 26.3 ng/mL (12/27/2014), 17.2 ng/mL (2/21/2015), 24.3 ng/mL (4/22/2015), 17.1 ng/mL (12/21/2016), and 18.9 ng/mL (4/12/2017). Its normal limit is 16.3 ng/mL.

Case 2: A 53-year-old woman (A.F.) visited my clinic on January 15, 2014. She told me that she had undergone a surgical operation on June 18, 2012 extirpating the upper lobe of her left lung due to presence of an adenocarcinoma, of which the longest diameter was 52 mm. In order to prevent a recurrence, she kept taking 100mg daily of TS-1 for 19 months after the operation. Then, she began to take aqueous solution of 4-Hydroxybenzaldehyde. Her initial daily dose was 35 mg, which she kept taking for 28 days then she took 50 mg daily for 20 days. I kept raising her daily dose, namely, 63 mg for 32 days, 83 mg for 36 days, 111 mg for 36 days, 167 mg for 30 days, 222 mg for 36 days, 333 mg for 36 days, 500 mg for 36 days, 750 mg for 88 days, 1 g for 90 days, and 1.5 g for 44 days. Then, I changed my prescription to 1.5 g of the therapeutic agent as a 10-fold mixture with starch, starch being 9 times as much as the drug, every 2 days for 638 days. Her blood tests showed a mediocre stability in CEA (Carcino-embryonic antigen; a marker of most malignant tumors) and CYFRA(Cytokeratin 19 Fragments; a marker of adenocarcinoma and squamous cell carcinoma of lung) values as follows: CEA 4.1 ng/mL, CYFRA 2.1 ng/mL (1/29/2015), CEA 3.8 ng/mL, CYFRA 1.4 ng/mL (5/28/2015), CEA 3.6 ng/mL, CYFRA 1.6 ng/mL (2/4/2016), CEA 3.4 ng/mL, CYFRA 1.7 ng/mL (4/25/2016), and CEA 2.8 ng/mL, CYFRA 1.2 ng/mL (1/12/2017). Their normal limits are 5.0 ng/mL and 2.2 ng/mL, respectively. Both of these patients are currently enjoying apparently healthy lives taking the agent continuously.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 498
  • [From(publication date):
    September-2017 - Jun 22, 2018]
  • Breakdown by view type
  • HTML page views : 443
  • PDF downloads : 55
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7